Balsalazide
From Wikipedia, the free encyclopedia
 |
|
|
Balsalazide
|
|
| Systematic (IUPAC) name | |
| 5-[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl-2-hydroxy-benzoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | A07 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H15N3O6 |
| Mol. mass | 357.318 g/mol |
| Pharmacokinetic data | |
| Bioavailability | <1% |
| Protein binding | ≥99% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
POM [UK] |
| Routes | ? |
Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK.
The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt.
Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of Ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.
